<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5760-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOXAFIL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        POSACONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2491.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" N.V. Organon" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             N.V. Organon
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Noxafil contains a medicine called posaconazole. This belongs to a group of medicines called &ldquo;antifungals&rdquo;. It is used to prevent and treat many different fungal infections.</p><p>&nbsp;</p><p>This medicine works by killing or stopping the growth of some types of fungi that can cause infections.</p><p><s>&nbsp;</s></p><p>Noxafil can be used in adults to treat fungal infections caused by fungi of the Aspergillus family.</p><p>&nbsp;</p><p>Noxafil can be used in adults and children from 2&nbsp;years of age weighing more than 40 kg to treat the following types of fungal infections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by fungi of the <em>Aspergillus</em> family that have not improved during treatment with the &nbsp;antifungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by fungi of the <em>Fusarium</em> family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by fungi that cause the conditions known as &ldquo;chromoblastomycosis&rdquo; and &ldquo;mycetoma&rdquo; that have not improved during treatment with itraconazole or when itraconazole has had to be stopped;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by a fungus called <em>Coccidioides</em> that have not improved during treatment with one or more of amphotericin B, itraconazole or fluconazole or when these medicines have had to be stopped.</p><p>&nbsp;</p><p>This medicine can also be used to prevent fungal infections in adults and children from 2&nbsp;years of age weighing more than 40 kg who are at high‑risk of getting a fungal infection, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients who have a weak immune system due to having chemotherapy for &ldquo;acute myelogenous leukaemia&rdquo; (AML) or &ldquo;myelodysplastic syndromes&rdquo; (MDS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients having &ldquo;high-dose immunosuppressive therapy&rdquo; after &ldquo;hematopoietic stem cell transplant&rdquo; (HSCT).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Do not take Noxafil</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to posaconazole or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking: terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, any medicines that contain &ldquo;ergot alkaloids&rdquo; such as ergotamine or dihydroergotamine, or a &ldquo;statin&rdquo; such as simvastatin, atorvastatin or lovastatin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have just started taking venetoclax or your venetoclax dose is being slowly increased for treatment of chronic lymphocytic leukaemia (CLL)</p><p>&nbsp;</p><p>Do not take Noxafil if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Noxafil.</p><p>&nbsp;</p><p>See &ldquo;Other medicines and Noxafil&rdquo; below for more information including information on other medicines which may interact with Noxafil.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Noxafil if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had an allergic reaction to another antifungal medicine such as ketoconazole, fluconazole, itraconazole or voriconazole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have ever had liver problems. You may need to have blood tests while you are taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop severe diarrhoea or vomiting, as these conditions may limit the effectiveness of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an abnormal heart rhythm tracing (ECG) that shows a problem called long QTc interval</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a weakness of the heart muscle or heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a very slow heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart rhythm disturbance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have any problem with potassium, magnesium or calcium levels in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking vincristine, vinblastine and other &ldquo;vinca alkaloids&rdquo; (medicines used to treat cancer).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking venetoclax (a medicine used to treat cancer).</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Noxafil.</p><p>&nbsp;</p><p>If you develop severe diarrhoea or vomiting (being sick) while taking Noxafil, talk to your doctor, pharmacist or nurse straight away, as this may stop it from working properly. See section&nbsp;4 for more information.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Noxafil should not be given to children younger than 2&nbsp;years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Noxafil</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Do not take Noxafil if you are taking any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; terfenadine (used to treat allergies)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; astemizole (used to treat allergies)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisapride (used to treat stomach problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pimozide (used to treat symptoms of Tourette&#39;s and mental illness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halofantrine (used to treat malaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine (used to treat abnormal heart rhythms).</p><p>Noxafil can increase the amount of these medicines in the blood which may lead to very serious changes to your heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines that contain &ldquo;ergot alkaloids&rdquo; such as ergotamine or dihydroergotamine used to treat migraines. Noxafil can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a &ldquo;statin&rdquo; such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; venetoclax when used at the start of the treatment of a type of cancer, chronic lymphocytic leukaemia (CLL)</p><p>&nbsp;</p><p>Do not take Noxafil if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><u>Other medicines</u></p><p>Look at the list of medicines given above that must not be taken while you are taking Noxafil. In addition to the medicines named above there are other medicines that carry a risk of rhythm problems that may be greater when they are taken with Noxafil. Please make sure you tell your doctor about all the medicines you are taking (prescribed or non-prescribed).</p><p>&nbsp;</p><p>Certain medicines may increase the risk of side effects of Noxafil by increasing the amount of Noxafil in the blood.</p><p>&nbsp;</p><p>The following medicines may decrease the effectiveness of Noxafil by decreasing the amount of Noxafil in the blood:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin and rifampicin (used to treat certain infections). If you are already taking rifabutin, you will need a blood test and you will need to look out for some possible side effects of rifabutin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine, phenobarbital or primidone (used to treat or prevent fits).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz and fosamprenavir used to treat HIV infection.</p><p>&nbsp;</p><p>Noxafil may possibly increase the risk of side effects of some other medicines by increasing the amount of these medicines in the blood. These medicines include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vincristine, vinblastine and other &ldquo;vinca alkaloids&rdquo; (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;venetoclax (used to treat cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (used during or after transplant surgery)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus and sirolimus (used during or after transplant surgery)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin (used to treat certain infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat HIV called protease inhibitors (including lopinavir and atazanavir, which are given with ritonavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam, triazolam, alprazolam or other &ldquo;benzodiazepines&rdquo; (used as sedatives or muscle relaxants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem, verapamil, nifedipine, nisoldipine or other &ldquo;calcium channel blockers&rdquo; (used to treat high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin (used to treat heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glipizide or other &ldquo;sulfonylureas&rdquo; (used to treat high blood sugar)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all-trans retinoic acid (ATRA), also called tretinoin (used to treat certain blood cancers).</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Noxafil.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Tell your doctor if you are or think you are pregnant before you start to take Noxafil.</p><p>Do not take Noxafil if you are pregnant unless you are told to by your doctor.</p><p>If you are a woman who could become pregnant you should use effective contraception while you are taking this medicine. If you become pregnant while you are taking Noxafil, contact your doctor straight away.</p><p><strong>&nbsp;</strong></p><p>Do not breast-feed while taking Noxafil. This is because small amounts may pass into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel dizzy, sleepy, or have blurred vision while taking Noxafil, which may affect your ability to drive or use tools or machines. If this happens, do not drive or use any tools or machines and contact your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Noxafil contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not switch between Noxafil tablets and Noxafil oral suspension without talking to your doctor or pharmacist because it may result in a lack of efficacy or an increased risk of adverse reactions.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The usual dose is 300&nbsp;mg (three 100&nbsp;mg tablets) twice a day on the first day, then 300&nbsp;mg (three 100&nbsp;mg tablets) once a day, thereafter.</p><p>&nbsp;</p><p>The length of treatment may depend on the type of infection that you have and may be individually adapted for you by your doctor. Do not adapt your dose yourself before consulting your doctor or change your treatment regimen.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with some water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not crush, chew, break or dissolve the tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablets may be taken with or without food.</p><p>&nbsp;</p><p><strong>If you take more Noxafil than you should</strong></p><p>If you think that you may have taken too much Noxafil, talk to a doctor or go to the hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to take Noxafil</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose, take it as soon as you remember it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Tell</strong><strong> your doctor, pharmacist or nurse straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea or vomit (feeling or being sick), diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of liver problems - these include yellowing of your skin or whites of the eyes, unusually dark urine or pale faeces, feeling sick for no reason, stomach problems, loss of appetite or unusual tiredness or weakness, an increase in liver enzymes shown up in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Tell your doctor, pharmacist or nurse if you notice any of the following side effects:</p><p>&nbsp;</p><p><u>Common: the following may affect up to 1 in 10 people</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in the salt level in your blood shown in blood tests - signs include feeling confused or weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal skin sensations, such as numbness, tingling, itching, creeping, pricking or burning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium levels &ndash; shown up in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low magnesium levels &ndash; shown up in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn (a burning sensation in the chest rising up to the throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of &ldquo;neutrophils&rdquo; a type of white blood cell (neutropenia) &ndash; this can make you more likely to get infections and be shown up in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, dizzy, tired or sleepy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rectal discomfort</p><p>&nbsp;</p><p><u>Uncommon: the following </u><u>may affect up to 1 in 100 people</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia - signs include headaches, feeling tired or dizzy, being short of breath or looking pale and a low level of haemoglobin shown up in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of platelets (thrombocytopenia) shown in blood tests &ndash; this may lead to bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of &ldquo;leukocytes&rdquo; a type of white blood cell (leukopenia) shown in blood tests &ndash; this can make you more likely to get infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of &ldquo;eosinophils&rdquo; a type of white blood cell (eosinophilia) &ndash; this can happen if you have inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart rhythm problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (convulsions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage (neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm &ndash; shown up on a heart trace (ECG), palpitations, slow or fast heartbeat, high or low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (pancreatitis) &ndash; this may cause severe stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oxygen supply to the spleen is interrupted (splenic infarction) - this may cause severe stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney problems &ndash; signs include passing more or less urine, that is a different colour than usual</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood levels of creatinine &ndash; shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe sharp chest pain when breathing in (pleuritic pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of lymph glands (lymphadenopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced feeling of sensitivity especially on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high or low blood sugar levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (alopecia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shivering, feeling generally unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, back or neck pain, pain in arms or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water retention (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual problems (abnormal vaginal bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being completely or partially unable to talk</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams, or difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with co-ordination or balance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mucosal inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stuffy nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling bloated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild to severe nausea, vomiting, cramps and diarrhoea, usually caused by a virus, stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; belching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling jittery</p><p>&nbsp;</p><p><u>Rare: the following </u><u>may affect up to 1 in 1,000 people</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia &ndash; signs include feeling short of breath and producing discoloured phlegm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure in the blood vessels in the lungs (pulmonary hypertension) this can cause serious damage to your lungs and heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood problems such as unusual blood clotting or prolonged bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions, including widespread blistering rash and skin peeling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mental problems such as hearing voices or seeing things that are not there</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having problems thinking or talking, having jerking movements, especially in your hands that you cannot control</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke &ndash; signs include pain, weakness, numbness, or tingling in the limbs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having a blind or dark spot in your field of vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure or heart attack which could lead to the heart stopping beating and death, heart rhythm problems, with sudden death</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in your legs (deep vein thrombosis) &ndash; signs include intense pain or swelling of the legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in your lungs (pulmonary embolism) &ndash; signs include feeling short of breath or pain while breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into your stomach or gut &ndash; signs include vomiting blood or passing blood in your stool</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blockage in your gut (intestinal obstruction) especially in the &ldquo;ileum&rdquo;. The blockage will prevent the contents of your intestine from passing through to the lower bowel signs include feeling bloated, vomiting, severe constipation, loss of appetite, and cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;haemolytic uraemic syndrome&rdquo; when red blood cells breakup (haemolysis) which may happen with or without kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;pancytopenia&rdquo; low level of all blood cells (red and white blood cells and platelets) shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large purple discolourations on the skin (thrombotic thrombocytopenic purpura)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenal glands not working properly &ndash; this may cause weakness, tiredness, loss of appetite, skin discolouration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pituitary gland not working properly &ndash; this may cause low blood levels of some hormones that affect the function of the male or female sex organs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pseudoaldosteronism, which results in high blood pressure with a low potassium level (shown in blood test)</p><p>&nbsp;</p><p><u>Not known: frequency cannot be estimated from the available data</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some patients have also reported feeling confused after taking Noxafil.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you notice any of the side effects listed above.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA&rdquo; By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the blister after EXP. The expiry date is written in both blister &amp; outer pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance in Noxafil is posaconazole. Each tablet contains 100 mg of posaconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: hypromellose acetate succinate; cellulose, microcrystalline; hydroxypropylcellulose (E463); silica dental type; croscarmellose sodium; magnesium stearate, polyvinyl alcohol, macrogol 3350, titanium dioxide (E171), talc, iron oxide yellow (E172).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Noxafil gastro-resistant tablets are yellow-coated and capsule-shaped, debossed “100” on one side packaged in a blister in cartons of 24 (2x12) or 96 (8x12) tablets.



Not all pack sizes may be marketed.





Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder</p><p>Merck Sharp &amp; Dohme (UK) Limited</p><p>120 Moorgate</p><p>London</p><p>EC2M 6UR</p><p>United Kingdom</p><p>&nbsp;</p><p><u>Manufacturer</u></p><p>N.V. Organon&nbsp;</p><p>Kloosterstraat 6, 5349 AB Oss</p><p>The Netherlands</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised Oct 2022

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	GCC States: 
Please contact the relevant competent authority.

This is a Medicament
-	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to
Instructions are dangerous for you.
-	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
-	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-	Do not by yourself interrupt the period of treatment prescribed for you.
-	Do not repeat the same prescription without consulting your doctor.
-	Keep all medicaments out of reach of children.

Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نوكسافيل على مادة فعالة تُدعى بوساكونازول. ينتمي هذا الدواء لمجموعة من الأدوية تسمى &quot;مُضَادّات الفِطريّات&quot;. وهو يستخدم للوقاية من أنواع مختلفة من العدوى الفِطريّة وعلاجها.</p><p dir="RTL">يعمل هذا الدواء عن طريق قتل بعض أنواع الفطريات التي يمكن أن تسبب العدوى أو إيقاف نموها.</p><p dir="RTL">يمكن استخدام نوكسافيل لدى البالغين لعلاج الالتهابات الفطرية الناجمة عن الفطريات من عائلة أسبيرقيلوس.</p><p dir="RTL">يمكن استخدام لدى في البالغين والأطفال من عمر سنتين و وزنهم أكثر من 40 كجم لعلاج الأنواع التالية من الالتهابات الفطرية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها فطريات عائلة <em>الرشاشيات</em> التي لم تتحسن خلال العلاج باستخدام الأدوية المضادة للفطريات أمفوتريسين ب أو إتراكونازول أو عندما يكون من الضروري إيقاف هذه الأدوية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها فطريات عائلة <em>المغزلاويات</em> التي لم تتحسن خلال العلاج باستخدام أمفوتريسين ب&nbsp; أو عندما يكون من الضروري إيقافه،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها فطريات تسبب الحالات المسماة &quot;الفطار البرعمي الصبغي&quot; و&quot;الورم الفطري&quot; التي لم تتحسن خلال العلاج باستخدام إتراكونازول أو عندما يكون من الضروري إيقاف إتراكونازول،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها فطريات عائلة <em>الكروانية اللدودة</em> التي لم تتحسن خلال العلاج باستخدام واحد أو أكثر من أدوية أمفوتريسين ب أو إتراكونازول أو&nbsp; فلوكونازول أو عندما يكون من الضروري إيقاف هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام الدواء كذلك للوقاية من العدوى الفطرية لدى البالغين والأطفال من عمر سنتين بوزن أكثر من 40 كجم</p><p dir="RTL">و الأكثر عُرضة لخطر الإصابة بالعدوى الفطرية، مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى المصابون بضعف الجهاز المناعي بسبب خضوعهم للعلاج الكيميائي لـ&quot;اللوكيميا النقوية الحادة&quot; (AML) أو &quot;متلازمة خلل التنسج التقوي&quot; (MDS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يتلقون &quot;العلاج المثبط للمناعة بجرعة عالية&quot; بعد &quot;زراعة الخلايا الجذعية المكونة للدم&quot; (HSCT).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول نوكسافيل في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بالحساسية تجاه بوساكونازول أو أي من المكونات الأخرى لهذا الدواء (مذكورة في البند 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول: تيرفينادرين، آستيميزول، سيسابريد، بيموزيد، هالوفانترين، كينيدين، وأي أدوية تحتوي &quot;قلوانيات الإرغوت&quot; مثل إرغوتامين أو دايهيدروإرغوتامين، أو أحد &quot;الستاتينات&quot; مثل سيمفاستاتين، أو أتورفاستاتين أو لوفاستاتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد بدأت للتو في تناول فينيتوكلاكس أو يتم زيادة جرعة فينيتوكلاكس ببطء لعلاج سرطان الدم اللمفاوي المزمن</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول نوكسافيل إن كان أي مما سبق ينطبق عليك. إن لم تكن متأكدًا، استشر الطبيب أو الصيدلي قبل تناول نوكسافيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر &quot;الأدوية الأخرى والدواء نوكسافيل&quot; أدناه لمزيد من المعلومات بما في ذلك المعلومات بخصوص الأدوية الأخرى التي قد تتفاعل مع نوكسافيل.</p><p dir="RTL">&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL">استشر الطبيب، أو الصيدلي أو الممرضة قبل تناول نوكسافيل في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا أو سبقت إصابتك بتفاعل حساسي تجاه دواء آخر مضاد للفطريات مثل كيتوكونازول، أو فلوكونازول، أو إتراكونازول أو فوريكونازول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا أو سبقت إصابتك بمشكلات كبدية. قد تحتاج للخضوع لاختبارات للدم خلال تناول هذا الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بالإسهال أو القيء الشديد حيث قد تحد تلك الحالات من فاعلية هذا الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا باضطراب تخطيط عضلة القلب الكهربائي (ECG) الذي يُظهر مشكلة تسمى فاصل (QTc) الطويل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بضعف عضلة القلب أو قصور عضلة القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بتباطؤ نبض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا باضطراب ضربات &nbsp;القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بأي مشكلة بخصوص مستويات البوتاسيوم، أو الماغنسيوم أو الكالسيوم في دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول فينبلاستين، فينكريستسن وقلويدات أخرى &quot;فينكا&quot; (الأدوية المستخدمة لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تتناول فينيتوكلاكس (دواء يستخدم لعلاج السرطان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كان أي مما سبق ينطبق عليك (أو إن لم تكن متأكدًا)، استشر الطبيب، أو الصيدلي أو الممرضة قبل تناول نوكسافيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن أصبت بإسهال أو قيء شديد (إعياء) خلال تناول نوكسافيل، استشر الطبيب، أو الصيدلي أو الممرضة فورًا، حيث قد يمنعه ذلك من العمل بفاعلية. انظر البند 4 لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p>الأطفال</p><p dir="RTL">لا ينبغي استخدام نوكسافيل للأطفال (أصغر من سنتين)</p><p>الأدوية الأخرى والدواء نوكسافيل</p><p dir="RTL">أبلغ الطبيب أو الصيدلي إن كنت تتناول ، أو إن تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p>لا تتناول نوكسافيل إن كنت تتناول أيًا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيرفينادرين (يستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آستيميزول (يستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (يستخدم لعلاج مشكلات المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد (يستخدم لعلاج مرض توريت والمرض العقلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين (يستخدم لعلاج الملاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (يستخدم لعلاج اضطراب ضربات القلب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يزيد نوكسافيل كميّة هذه الأدوية في الدّم مما قد يؤدي بدوره لتغيرات بالغة الخطورة بنظم قلبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيّ أدوية تحتوي &quot;قلوانيات الإرغوت&quot; مثل إرغوتامين أو دايهيدروإرغوتامين التي تستخدم لعلاج الصداع النصفي. يمكن أن يزيد نوكسافيل كمية هذه الأدوية في الدم وهو ما قد يؤدي بدوره لنقص شديد لتدفق الدم إلى أصابع يديك أو قدميك وهو ما قد يؤدي للإضرار بهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد &quot;الستاتينات&quot; مثل سيمفاستاتين، أو أتورفاستاتين أو لوفاستاتين التي تستخدم لعلاج ارتفاع الكولسترول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوكلاكس عند استخدامه في بداية علاج نوع من السرطان ، سرطان الدم اللمفاوي المزمن</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم نوكسافيل إن كان أي مما سبق ينطبق عليك. إن لم تكن متأكدًا، استشر الطبيب أو الصيدلي أو الممرضة قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأدوية الأخرى</u></p><p dir="RTL">طالع قائمة الأدوية المذكورة أعلاه والتي لا يجب أن تتناولها خلال تناول نوكسافيل. بالإضافة للأدوية المسماة أعلاه فتوجد أدوية أخرى قد تعرضك لخطر مشكلات في ضربات القلب والتي قد تزداد شدتها عند تناولها مع نوكسافيل. برجاء التأكد من إبلاغ طبيبك بكل ما تتناوله من أدوية (الموصوفة أو غير الموصوفة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تزيد بعض الأدوية خطر الأعراض الجانبية لدواء نوكسافيل عن طريق زيادة كمية نوكسافيل في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحد الأدوية التالية من فاعلية نوكسافيل عن طريق الحد من كمية نوكسافيل في الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابيوتين وريفامبيسين (يستخدمان لعلاج أنواع بعينها من العدوى) إن كنت تتناول ريفابيوتين بالفعل، فستحتاج لاختبار للدم وستحتاج لتحري بعض الأعراض الجانبية الممكنة للدواء ريفابيوتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين، كاربامازيبين، الفينوباربيتال أو بريميدون (تستخدم لعلاج أو منع نوبات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافايرينز وفوسامبرينافير المستخدمان في علاج عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد نوكسافيل خطر الأعراض الجانبية لبعض الأدوية الأخرى عن طريق زيادة كمية هذه الأدوية في الدم. تتضمن هذه الأدوية ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينكريستين، فينبلاستين وغير ذلك من &quot;قلوانيات الفينكا&quot; (تستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;فينيتوكلاكس (يستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يستخدم خلال عمليات زراعة الأعضاء أو بعدها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليماس وسيروليماس (يستخدمان خلال عمليات زراعة الأعضاء أو بعدها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابيوتين (يستخدم لعلاج أنواع بعينها من العدوى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية التي تسمى مثبطات البروتييز (تتضمن لوبينافير وآتازانافير، والتي تعطى مع ريتونافير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام، أو ترايازولام، أو ألبرازولام أو غير ذلك من أدوية &quot;البنزوديازيبينات&quot; (تستخدم كمهدئات أو مرخيات للعضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم، أو فيراباميل، أو نيفيديبين، أو نيزولديبين أو غيرها من &quot;حاصرات قناة الكالسيوم&quot; (تستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (يستخدم لعلاج قصور عضلة القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكلازيد أو غير ذلك من أدوية &quot;سالفونيل يوريا&quot; (تستخدم لعلاج ارتفاع سكر الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كافة أحماض الريتينويك (ATRA) &nbsp;وتسمى أيضا تريتينوين (تستخدم لعلاج بعض سرطانات الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كان أي مما سبق ينطبق عليك (أو إن لم تكن متأكدًا)، استشر الطبيب، أو الصيدلي قبل تناول نوكسافيل.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">أبلغي الطبيب إن كنت تعتقدين بأنكِ حاملٌ قبل بدء استخدام نوكسافيل. لا تتناولي نوكسافيل إن كنتِ حاملًا ما لم يبلغك الطبيب بغير ذلك.</p><p dir="RTL">إن كنتِ امرأةً بإمكانها الحمل فعليكِ استخدام وسيلة فعالة لمنع الحمل خلال استخدامك هذا الدواء. في حال حدوث حمل خلال تناول نوكسافيل، فاتصلي بالطبيب فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقومي بالرضاعة الطبيعية خلال تناول &nbsp;نوكسافيل. يرجع ذلك لأن كميات صغيرة منه قد تمر في لبن الأم.</p><p dir="RTL">&nbsp;</p><p>قيادة المركبات واستخدام الآلات</p><p dir="RTL">قد تشعر بالدوخة، أو يغشى بصرك خلال تناول نوكسافيل، وهو ما قد يؤثر على قدرتك على قيادة المركبات واستخدام الأدوات أو الآلات. إن حدث ذلك، فلا تقم بقيادة المركبات أو استخدام أي أدوات أو آلات واتصل بالطبيب.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>يحتوي نوكسافيل على الصوديوم</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل قرص ، أي أنه &quot;خال من الصوديوم&quot; بشكل أساس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تَقُمْ بالتبديل بين استخدام أقراص نوكسافيل ومحلول نوكسافيل المعُلق الذي يُعطى عن طريق الفم دون استشارة الطبيب أو الصيدلي&nbsp; حيث أن ذلك قد يؤدي إلى عدم الفاعلية أو إلى زيادة خطر التفاعلات الجانبية.</p><p dir="RTL">دائمًا ينبغي تناول هذا الدواء حسب إرشادات الطبيب أو الصيدلي تمامًا. راجع طبيبك أو الصيدلي إن كنت في شك من ذلك.</p><p dir="RTL">&nbsp;</p><p>مقدار الجرعة</p><p dir="RTL">الجرعة المعتادة هي 300 ملغم (3 أقراص بتركيز 100 ملغم) مرتين يوميًا في اليوم الأول، ثم 300 ملغم (3 أقراص بتركيز 100 ملغم) مرة يوميًا، بعد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد مدة العلاج على نوع العدوى التي تعانيها ويمكن أن يعدلها الطبيب بحسب حالتك الفردية. لا تعدل الجرعة من تلقاء نفسك دون استشارة الطبيب ولا تغير نظام علاجك.</p><p>&nbsp;</p><p>استخدام هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اِبْلَع القرص كاملًا مع بعض الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تهشم القرص، أو تمضغه، أو تكسره أو تُذِبْه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك أن تتناول الأقراص مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p>إن تناولت أكثر مما يجب من نوكسافيل</p><p dir="RTL">إن شككت أنك تناولت أكثر مما يجب من نوكسافيل، استشر الطبيب أو اذهب للمستشفى فورًا.</p><p dir="RTL">&nbsp;</p><p>إن نسيت تناول نوكسافيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن نسيت إحدى الجرعات، فتناولها فور تذكرها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولكن، إن كان موعد الجرعة التالية قد أوشك، فتخطَّ الجرعة المنسية وعُد لجدول مواعيدك المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مزدوجة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كان لديك المزيد من الأسئلة بخصوص استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، وإن كانت لا تحدث في جميع الأشخاص الذين يتناولونه.</p><p dir="RTL">&nbsp;</p><p>الأعراض الجانبية الخطيرة</p><p dir="RTL"><strong>أبلغ الطبيب، أو الصيدلي أو الممرضة فورًا إن لاحظت أي من الأعراض الجانبية الخطيرة التالية - قد تحتاج للعلاج الطبي العاجل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء (الشعور بالإعياء أو الإصابة به)، والإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض المشاكل في الكبد- يتضمن ذلك اصفرار الجلد أو بياض العينين، و البول الداكن وشحوب البراز بصورة غير معتادة، والشعور بالإعياء دون سبب، ومشكلات المعدة، وضعف الشهية أو التعب أو الضعف غير المعتاد، وزيادة الإنزيمات الكبدية التي تظهر في اختبارات الدم..</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية</p><p>&nbsp;</p><p>أعراض&nbsp; جانبية أخرى</p><p dir="RTL">أبلغ الطبيب، أو الصيدلي أو الممرضة إن لاحظت أيًا من الأعراض الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة: قد تصيب الأعراض الجانبية التالية حتى شخص واحد من كل 10 أشخاص</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير مستوى الأملاح في دمك كما يظهر في اختبارات الدم - تتضمن الأعراض&nbsp; الشعور بالارتباك أو الضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحسُّس الجلد الغير الطبيعي، كالخدران، أو الدغدغة، أو الحكة، أو التنميل، أو الوخز أو الحُرقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم &ndash; كما يظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الماغنسيوم&nbsp; &ndash; كما يظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية، وألم المعدة أو تهيجها، وغازات البطن، وجفاف الفم، وتغيرات في تذوقك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُرقة المعدة (إحساس بالحرقة في الصدر يرتفع إلى الحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات &quot;الخلايا المتعادلة&quot; وهي نوع من كريات الدم البيضاء &quot;(نقص الخلايا المتعادلة) - يمكن أن يزيد ذلك من احتمال تعرضك للعدوى ويتضح من خلال اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف، أو الدوخة، أو الإرهاق أو النوام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة في منطقة الشرج</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير شائعة: قد تصيب الأعراض الجانبية التالية حتى شخص واحد من كل 100 شخص</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم - تتضمن الأعراض الصداع، والشعور بالإرهاق أو الدوخة، والشعور بضيق التنفس أو المظهر الشاحب وانخفاض مستوى الهيموغلوبين كما يتضح في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدموية (نقص صفيحات الدم) &ndash; كما يظهر في اختبارات الدم - قد يؤدي ذلك للنزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الخلايا البيضاء&quot; وهي نوع من كريات الدم البيضاء (نقص الخلايا البيضاء) &ndash; كما يظهر في اختبارات الدم - قد يجعلك ذلك أكثر عرضة للإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى &quot;الخلايا اليوزينية&quot; وهي نوع من كريات الدم البيضاء (فرط الخلايا اليوزينية) - ويمكن أن يحدث ذلك إن أصبت بالتهاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات &nbsp;القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الصرع (التشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضرر الأعصاب (اعتلال الأعصاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات&nbsp; القلب &ndash; كما يظهر في تخطيط عضلة القلب الكهربائي (ECG)، أو الخفقان، أو تباطؤ النبض القلبي أو تسارعه، أو ارتفاع ضغط الدم أو انخفاضه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (الالتهاب البنكرياسي) - قد يسبب ذلك ألماً شديدًا في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعاقة إمداد الطحال بالأكسجين (احتشاء الطحال) - قد يسبب ذلك ألمًا شديدًا في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات خطيرة في الكلى - تتضمن الأعراض زيادة معدل التبول أو نقص كمية البول، وقد يتغير لونه عن الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الكرياتينين في الدم - كما يظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال، والفواق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر الحاد الشديد عند الشهيق (ألم التهاب الجنبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العقد الليمفاوية (اعتلال العقد الليمفاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشعور بالحساسية وبخاصةٍ في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات سكر الدم أو انخفاضها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الإبصار، والحساسية للضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الثعلبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة، والشعور بالإعياء بصفة عامة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم، ألم الظهر أو العنق، وألم الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس الماء (الوذم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الطمث (النزيف المهبلي غير الطبيعي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (الأرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الكلام كليًّا أو جزئيًّا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأحلام غير الطبيعية، أو صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات التناسق أو الاتزان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاج الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان البسيط إلى الشديد، والقيء، والتقلصات والإسهال، وهوما يحدث عادةً نتيجة فيروس ما، وألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعصبية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نادرة: قد تصيب تلك </u><u>الأعراض </u><u>&nbsp;الجانبية&nbsp; حتى شخص واحد من كل 1,000 شخص.</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي - تتضمن الأعراض الشعور بضيق التنفس وإنتاج بلغم غريب اللون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم في الأوعية الدموية في الرئتين (ارتفاع ضغط الدم الرئوي) وهو ما قد يسبب تضررًا كبيرًا لرئتيك ولقلبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الدم مثل تجلط الدم بشكل غير معتاد أو النزيف المطول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية الشديدة، بما في ذلك الطفح الجلدي النقطي واسع الانتشار وتقشر الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشكلات العقلية كسماع أصوات أو إبصار أشياء غير حقيقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمشكلات في التفكير أو الكلام، والإصابة بالرعشة، خاصةً في يديك دون أن تستطيع السيطرة عليها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية - تتضمن العلامات الألم، أو الضعف، أو التنميل، أو الدغدغة في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة ببقعة عمياء أو داكنة ضمن نطاق الإبصار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور عضلة القلب أو الجلطة الذي قد تؤدي لسكتة القلبية والوفاة، و اضطراب ضربات&nbsp; القلب ، مع الوفاة المفاجئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطات الدموية في ساقيك (التخثر الوريدي العميق) - تتضمن الأعراض الألم الشديد في الساقين أو تورمهما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطات الدموية في رئتيك (التجلط الرئوي) - تتضمن الأعراض الشعور بضيق التنفس أو الألم المصاحب للتنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف في المعدة أو الأمعاء - تتضمن العلامات القيء الدموي أو البراز الدموي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء (الانسداد المعوي) وخاصةً في &quot;اللفائفي&quot;. سيمنع الانسداد مرور محتويات الأمعاء إلى الجزء السفلي من الأمعاء وتتضمن العلامات الشعور بالانتفاخ، والقيء، والإمساك الشديد، وضعف الشهية، والتقلصات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;المتلازمة اليوريمية الحالّة للدم&quot; عند تكسر كريات الدم الحمراء (الانحلال الدموي) وهو ما قد يحدث مع الفشل الكلوي أو بدونه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;النقص الشامل للخلايا&quot; أي انخفاض مستويات جميع خلايا الدم (كريات الدم الحمراء والبيضاء والصفيحات) كما يتضح في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مناطق كبيرة قرمزية اللون في الجلد (فرفرية نقص الصفيحات الخثارية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الإبصار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظيفة الغدتين الكظريتين - قد يسبب ذلك الضعف، والتعب ، وضعف الشهية ، وتغير لون الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظيفة الغدة النخامية - قد يسبب ذلك نقص مستويات بعض الهرمونات في الدم مما قد يؤثر على وظيفة الأعضاء التناسلية الذكرية أو الأنثوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pseudoaldosteronism الذي يؤدي إلى ارتفاع ضغط الدم مع انخفاض مستوى البوتاسيوم (كما هو موضح في اختبار الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير معروف: لا يمكن تقدير التردد من البيانات المتاحة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;وقد أبلغ بعض المرضى أيضا شعور بالارتباك بعد أخذ نوكسافيل.</p><p>&nbsp;</p><p dir="RTL">أبلغ الطبيب، أو الصيدلي أو الممرضة إن لاحظت أيًّا من الأعراض&nbsp; الجانبية المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p>للإبلاغ عن الأعراض الجانبية</p><p dir="RTL">إن أصبت بأي أعراض جانبية، فأبلغ طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي أعراض جانبية غير مذكورة في هذه النشرة. يمكنك الإبلاغ عن أي أعراض جانبية مباشرة عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء، بالمملكة العربية السعودية &quot;. بإبلاغك عن الأعراض الجانبية ، يمكنك المساعدة في تقديم مزيد من المعلومات بخصوص أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على الشريط بعد الرمز EXP. تاريخ انتهاء الصلاحية مكتوب على كل من الشريط والعبوة الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في نوكسافيل هي بوساكونازول يحتوي كل قرص على 100 ملغم&nbsp; من بوساكونازول</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن باقي المكونات:</p><p dir="RTL">المكونات الأخرى هي: خلات الهيبروميلوز خلات سوستينات; السليلوز، البلورات الدقيقة؛ هيدروكسي بروبيلسليلوز (E463); نوع السيليكا الأسنان; كروسكارميلوز الصوديوم; ستيرات المغنيسيوم، كحول البوليفينيل، ماكروغول 3350، ثاني أكسيد التيتانيوم (E171)، التلك، أكسيد الحديد الأصفر (E172).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص نوكسافيل المقاومة للمعدة هي أقراص صفراء مغلفة على شكل كبسولات، محفور فيها &quot;100&quot; في أحد الجانبين ومعبئة في شريط داخل علبة كرتونية تحتوي على 24 (2 *12) أو 96 (8 * 12) قرصًا.</p><p dir="RTL">قد لا يتم تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المالكة لحقوق التسويق:</p><p dir="RTL">ميرك شارب آند دوهم المحدودة، 120 مورجيت، لندن، إي سي 2 إم 6 يو آر ، المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">إن في أورجانون</p><p dir="RTL">كلوستيرسترات 6 ،5349 إيه بي أوس</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ {اكتوبر 2022 م}
رقم النسخة (5)

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.
(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرف لك الدواء
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه و مخاطره
- لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Noxafil 100 mg gastro-resistant tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant tablet contains 100 mg of posaconazole. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablet (tablet)
Yellow-coated, capsule-shaped tablet of 17.5 mm length debossed with “100” on one side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invasive aspergillosis</p><p>&nbsp;</p><p>Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2&nbsp;years of age weighing more than 40&nbsp;kg and adults (see sections&nbsp;4.2 and&nbsp;5.1):</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.</p><p>&nbsp;</p><p>Refractoriness is defined as progression of infection or failure to improve after a minimum of 7&nbsp;days of prior therapeutic doses of effective antifungal therapy<em>.</em></p><p><strong>&nbsp;</strong></p><p>Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2&nbsp;years of age weighing more than 40&nbsp;kg and adults (see sections&nbsp;4.2 and 5.1):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high‑risk of developing invasive fungal infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high‑risk of developing invasive fungal infections.</p><p>&nbsp;</p><p>Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care of high‑risk patients for which posaconazole is indicated as prophylaxis.</p><p>&nbsp;</p><p><strong>Non-interchangeability</strong><strong> between Noxafil tablets and Noxafil oral suspension</strong></p><p><strong>&nbsp;</strong></p><p>The tablet is not to be used interchangeably with the oral suspension due to the differences between these two formulations in frequency of dosing, administration with food and plasma drug concentration achieved. Therefore, follow the specific dose recommendations for each formulation.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Noxafil is also available as 40&nbsp;mg/mL oral suspension, 300&nbsp;mg concentrate for solution for infusion, and 300&nbsp;mg gastro‑resistant powder and solvent for oral suspension. Noxafil tablets generally provide higher plasma drug exposures than Noxafil oral suspension under both fed and fasted conditions. Therefore, the tablets are the preferred formulation to optimise plasma concentrations.</p><p>&nbsp;</p><p>Recommended dose in paediatric patients from 2&nbsp;years of age weighing more than 40&nbsp;kg and in adults is shown in Table&nbsp;1.</p><p>&nbsp;</p><p>Noxafil gastro-resistant powder and solvent for oral suspension is recommended for oral use in paediatric patients 2&nbsp;years of age and older weighing 40&nbsp;kg or less. Refer to the gastro-resistant powder and solvent for oral suspension SmPC for additional dosing information.</p><p>&nbsp;</p><p><strong>Table&nbsp;1.</strong> Recommended dose in paediatric patients from 2&nbsp;years of age weighing more than 40&nbsp;kg and in adults according to indication</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dose and duration of therapy</strong></p><p>(See section&nbsp;5.2)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Treatment of invasive aspergillosis (only for adults)</p></td><td style="vertical-align:top"><p>Loading dose of 300&nbsp;mg (three 100&nbsp;mg tablets or 300&nbsp;mg concentrate for solution for infusion) twice a day on the first day, then 300&nbsp;mg (three 100&nbsp;mg tablets or 300&nbsp;mg concentrate for solution for infusion) once a day thereafter.</p><p>Each tablet dose may be taken without regard to food intake.</p><p>Recommended total duration of therapy is 6-12&nbsp;weeks.</p><p>Switching between intravenous and oral administration is appropriate when clinically indicated.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1<sup>st</sup> line therapy</p></td><td style="vertical-align:top"><p>Loading dose of 300&nbsp;mg (three 100&nbsp;mg tablets) twice a day on the first day, then 300&nbsp;mg (three 100&nbsp;mg tablets) once a day thereafter. Each dose may be taken without regard to food intake. Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prophylaxis of invasive fungal infections</p></td><td style="vertical-align:top"><p>Loading dose of 300&nbsp;mg (three 100&nbsp;mg tablets) twice a day on the first day, then 300&nbsp;mg (three 100&nbsp;mg tablets) once a day thereafter. Each dose may be taken without regard to food intake. Duration of therapy is based on recovery from neutropenia or immunosuppression. For patients with acute myelogenous leukaemia or myelodysplastic syndromes, prophylaxis with Noxafil should start several days before the anticipated onset of neutropenia and continue for 7&nbsp;days after the neutrophil count rises above 500&nbsp;cells per mm<sup>3</sup>.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>Limited data on the effect of hepatic impairment (including Child-Pugh C classification of chronic liver disease) on the pharmacokinetics of posaconazole demonstrate an increase in plasma exposure compared to subjects with normal hepatic function, but do not suggest that dose adjustment is necessary (see sections&nbsp;4.4 and 5.2). It is recommended to exercise caution due to the potential for higher plasma exposure.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of posaconazole in children aged below 2&nbsp;years have not been established.</p><p>No clinical data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use</p><p>&nbsp;</p><p>Noxafil gastro-resistant tablets may be taken with or without food (see section&nbsp;5.2). The tablets should be swallowed whole with water and should not be crushed, chewed, or broken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration with ergot alkaloids (see section 4.5).

Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5).

Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin (see section 4.5).


Co-administration during the initiation and dose-titration phase of venetoclax in Chronic Lymphocytic Leukaemia (CLL) patients (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>There is no information regarding cross-sensitivity between posaconazole and other azole antifungal agents. Caution should be used when prescribing posaconazole to patients with hypersensitivity to other azoles.</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>Hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin and/or clinical hepatitis) have been reported during treatment with posaconazole.<strong> </strong>Elevated liver function tests were generally reversible on discontinuation of therapy and in some instances these tests normalised without interruption of therapy. Rarely, more severe hepatic reactions with fatal outcomes have been reported.</p><p>Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients (see sections&nbsp;4.2 and 5.2).</p><p>&nbsp;</p><p><u>Monitoring of hepatic function</u></p><p>Liver function tests should be evaluated at the start of and during the course of posaconazole therapy. Patients who develop abnormal liver function tests during posaconazole therapy must be routinely monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of posaconazole should be considered if clinical signs and symptoms are consistent with development of liver disease.</p><p>&nbsp;</p><p><u>QTc prolongation</u></p><p>Some azoles have been associated with prolongation of the QTc interval. Posaconazole must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections&nbsp;4.3 and 4.5). Posaconazole should be administered with caution to patients with pro-arrhythmic conditions such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc prolongation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, especially in the presence of cardiac failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant use with medicinal products known to prolong the QTc interval (other than those mentioned in section&nbsp;4.3).</p><p>Electrolyte disturbances, especially those involving potassium, magnesium or calcium levels, should be monitored and corrected as necessary before and during posaconazole therapy.</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>Posaconazole is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4 (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Midazolam and other benzodiazepines</u></p><p>Due to the risk of prolonged sedation and possible respiratory depression co‑administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary. Dose adjustment of benzodiazepines metabolised by CYP3A4 should be considered (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Vincristine toxicity</u></p><p>Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus. Reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p>Venetoclax toxicity</p><p>Concomitant administration of strong CYP3A inhibitors, including posaconazole, with the CYP3A4 substrate venetoclax, may increase venetoclax toxicities, including the risk of tumour lysis syndrome (TLS) and neutropenia (see sections 4.3 and 4.5). Refer to the venetoclax SmPC for detailed guidance.</p><p>&nbsp;</p><p><u>Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz.</u></p><p>Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Plasma exposure</u></p><p>Posaconazole plasma concentrations following administration of posaconazole tablets are generally higher than those obtained with posaconazole oral suspension. Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Gastrointestinal dysfunction</u></p><p>There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea). Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Effects of other medicinal products on posaconazole</u></p><p>Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p‑glycoprotein (P-gp) efflux<em> in vitro</em>. Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively.</p><p>&nbsp;</p><p><em>Rifabutin</em></p><p>Rifabutin (300&nbsp;mg once a day) decreased the C<sub>max</sub> (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57&nbsp;% and 51&nbsp;%, respectively. Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of posaconazole on rifabutin plasma levels.</p><p>&nbsp;</p><p><em>Efavirenz</em></p><p>Efavirenz (400&nbsp;mg once a day) decreased the C<sub>max </sub>and AUC of posaconazole by 45&nbsp;% and 50&nbsp;%, respectively. Concomitant use of posaconazole and efavirenz should be avoided unless the benefit to the patient outweighs the risk.</p><p>&nbsp;</p><p><em>Fosamprenavir</em></p><p>Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. Repeat dose administration of fosamprenavir (700&nbsp;mg twice daily x 10&nbsp;days) decreased the C<sub>max</sub><sub> </sub>and AUC of posaconazole oral suspension (200&nbsp;mg once daily on the 1<sup>st</sup>&nbsp;day, 200&nbsp;mg twice daily on the 2<sup>nd</sup>&nbsp;day, then 400&nbsp;mg twice daily x 8&nbsp;Days) by 21&nbsp;% and 23&nbsp;%, respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.</p><p>&nbsp;</p><p><em>Phenytoin</em></p><p>Phenytoin (200&nbsp;mg once a day) decreased the C<sub>max</sub> and AUC of posaconazole by 41&nbsp;% and 50&nbsp;%, respectively. Concomitant use of posaconazole and phenytoin and similar inducers (e.g. carbamazepine, phenobarbital, primidone) should be avoided unless the benefit to the patient outweighs the risk.</p><p>&nbsp;</p><p><em>H<sub>2</sub> receptor antagonists and proton pump inhibitors</em></p><p>No clinically relevant effects were observed when posaconazole tablets are concomitantly used with antacids, H<sub>2</sub>-receptor antagonists and proton pump inhibitors.<em> </em>No dose adjustment of posaconazole tablets is required when posaconazole tablets are concomitantly used with antacids, H<sub>2</sub>-receptor antagonists and proton pump inhibitors.</p><p><u>&nbsp;</u></p><p><u>Effects of posaconazole on other medicinal products</u></p><p>Posaconazole is a potent inhibitor of CYP3A4. Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. Caution is advised during co-administration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced. If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed. Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose. The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients. The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient.</p><p>&nbsp;</p><p><em>Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)</em></p><p>Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see section&nbsp;4.3).</p><p>&nbsp;</p><p><em>Ergot alkaloids</em></p><p>Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism. Co-administration of posaconazole and ergot alkaloids is contraindicated (see section&nbsp;4.3).</p><p>&nbsp;</p><p><em>HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and atorvastatin)</em></p><p>Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4. Treatment with these HMG-CoA reductase inhibitors should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis (see section&nbsp;4.3).</p><p>&nbsp;</p><p><em>Vinca alkaloids</em></p><p>Most of the vinca alkaloids (e.g. vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.</p><p>&nbsp;</p><p><em>Rifabutin</em></p><p>Posaconazole increased the C<sub>max</sub> and AUC of rifabutin by 31&nbsp;% and 72&nbsp;%, respectively. Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended.</p><p>&nbsp;</p><p><em>Sirolimus</em></p><p>Repeat dose administration of posaconazole oral suspension (400&nbsp;mg twice daily for 16&nbsp;days) increased the C<sub>max</sub> and AUC of sirolimus (2&nbsp;mg single dose) an average of 6.7‑fold and 8.9‑fold (range 3.1 to 17.5‑fold), respectively, in healthy subjects. The effect of posaconazole on sirolimus in patients is unknown, but is expected to be variable due to the variable posaconazole exposure in patients. Co-administration of posaconazole with sirolimus is not recommended and should be avoided whenever possible. If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood. Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly<strong>.</strong> It should be noted that the relationship between sirolimus trough concentration and AUC is changed during co-administration with posaconazole. As a result, sirolimus trough concentrations that fall within the usual therapeutic range may result in sub-therapeutic levels. Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies.</p><p>&nbsp;</p><p><em>Ciclosporin</em></p><p>In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200&nbsp;mg once daily increased ciclosporin concentrations requiring dose reductions. Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies. When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose). Thereafter blood levels of ciclosporin should be monitored carefully during co-administration, and upon discontinuation of posaconazole treatment, and the dose of ciclosporin should be adjusted as necessary.</p><p>&nbsp;</p><p><em>Tacrolimus</em></p><p>Posaconazole increased C<sub>max</sub> and AUC of tacrolimus (0.05&nbsp;mg/kg body weight single dose) by 121&nbsp;% and 358&nbsp;%, respectively. Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies. When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose). Thereafter blood levels of tacrolimus should be monitored carefully during co-administration, and upon discontinuation of posaconazole, and the dose of tacrolimus should be adjusted as necessary.</p><p>&nbsp;</p><p><em>HIV Protease inhibitors</em></p><p>As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents. Following co-administration of posaconazole oral suspension (400&nbsp;mg twice daily) with atazanavir (300&nbsp;mg once daily) for 7&nbsp;days in healthy subjects C<sub>max</sub> and AUC of atazanavir increased by an average of 2.6‑fold and 3.7‑fold (range 1.2 to 26‑fold), respectively. Following co-administration of posaconazole oral suspension (400&nbsp;mg twice daily) with atazanavir and ritonavir (300/100&nbsp;mg once daily) for 7&nbsp;days in healthy subjects C<sub>max</sub> and AUC of atazanavir increased by an average of 1.5‑fold and 2.5‑fold (range 0.9 to 4.1‑fold), respectively. The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole.</p><p>&nbsp;</p><p><em>Midazolam and other benzodiazepines metabolised by CYP3A4</em></p><p>In a study in healthy volunteers posaconazole oral suspension (200&nbsp;mg once daily for 10&nbsp;days) increased the exposure (AUC) of intravenous midazolam (0.05&nbsp;mg/kg) by 83&nbsp;%. In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200&nbsp;mg twice daily for 7&nbsp;days) increased the C<sub>max</sub> and AUC of intravenous midazolam (0.4&nbsp;mg single dose) by an average of 1.3- and 4.6‑fold (range 1.7 to 6.4‑fold), respectively; Posaconazole oral suspension 400&nbsp;mg twice daily for 7&nbsp;days increased the intravenous midazolam C<sub>max</sub> and AUC by 1.6 and 6.2‑fold (range 1.6 to 7.6‑fold), respectively. Both doses of posaconazole increased C<sub>max</sub> and AUC of oral midazolam (2&nbsp;mg single oral dose) by 2.2 and 4.5‑fold, respectively. In addition, posaconazole oral suspension (200&nbsp;mg or 400&nbsp;mg) prolonged the mean terminal half‑life of midazolam from approximately 3‑4&nbsp;hours to 8‑10&nbsp;hours during co‑administration.</p><p>Due to the risk of prolonged sedation it is recommended that dose adjustments should be considered when posaconazole is administered concomitantly with any benzodiazepine that is metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine)</em></p><p>Frequent monitoring for adverse reactions and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole. Dose adjustment of calcium channel blockers may be required.</p><p>&nbsp;</p><p><em>Digoxin</em></p><p>Administration of other azoles has been associated with increases in digoxin levels. Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment.</p><p>&nbsp;</p><p><em>Sulfonylureas</em></p><p>Glucose concentrations decreased in some healthy volunteers when glipizide was co-administered with posaconazole. Monitoring of glucose concentrations is recommended in diabetic patients.</p><p><em>&nbsp;</em></p><p><em>All-trans retinoic acid (ATRA) or tretinoin</em></p><p>As ATRA is metabolised by the hepatic CYP450 enzymes, notably CYP3A4, concomitant administration with posaconazole, which is a strong inhibitor of CYP3A4, may lead to increased exposure to tretinoin resulting in an increased toxicity (especially hypercalcaemia). Serum calcium levels should be monitored and, if needed, appropriate dose adjustments of tretinoin should be considered during the treatment with posaconazole, and during the following days after treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Venetoclax</em></p><p>Compared with venetoclax 400 mg administered alone, co-administration of 300 mg posaconazole, a strong CYP3A inhibitor, with venetoclax 50 mg and 100 mg for 7 days in 12 patients, increased venetoclax C<sub>max</sub> to 1.6-fold and 1.9-fold, and AUC to 1.9-fold and 2.4-fold, respectively (see sections 4.3 and 4.4).</p><p>Refer to the venetoclax SmPC.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric</u><u> </u><u>population</u></p><p>Interaction studies have only been performed in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is insufficient information on the use of posaconazole in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Women of childbearing potential have to use effective contraception during treatment. Posaconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>Posaconazole is excreted into the milk of lactating rats (see section&nbsp;5.3). The excretion of posaconazole in human breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with posaconazole.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Posaconazole had no effect on fertility of male rats at doses up to 180&nbsp;mg/kg (3.4 times the 300‑mg tablet based on steady-state plasma concentrations in patients) or female rats at a dose up to 45&nbsp;mg/kg (2.6 times the 300‑mg tablet based on steady-state plasma concentrations in patients). There is no clinical experience assessing the impact of posaconazole on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since certain adverse reactions (e.g. dizziness, somnolence, etc.) have been reported with posaconazole use, which potentially may affect driving/operating machinery, caution needs to be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Safety data mainly derive from studies with the oral suspension.</p><p>The safety of posaconazole oral suspension has been assessed in &gt;&nbsp;2,400&nbsp;patients and healthy volunteers enrolled in clinical studies and from post-marketing experience. The most frequently reported serious related adverse reactions included nausea, vomiting, diarrhoea, pyrexia, and increased bilirubin.</p><p>&nbsp;</p><p><em><u>Posaconazole tablets </u></em></p><p>The safety of posaconazole tablet has been assessed in 104 healthy volunteers and 230 patients enrolled in a clinical study of antifungal prophylaxis.</p><p>The safety of posaconazole concentrate for solution for infusion and posaconazole tablet has been assessed in 288 patients enrolled in a clinical study of aspergillosis of whom 161 patients received the concentrate for solution for infusion and 127 patients received the tablet formulation.</p><p>&nbsp;</p><p>The tablet formulation was investigated in AML and MDS patients and those after HSCT with or at risk for Graft versus Host Disease (GVHD) only. Maximum duration of exposure to the tablet formulation was shorter than with the oral suspension. Plasma exposure resulting from the tablet formulation was higher than observed with the oral suspension.</p><p>&nbsp;</p><p>The safety of posaconazole tablets has been assessed in 230&nbsp;patients enrolled in the pivotal clinical study. Patients were enrolled in a non-comparative pharmacokinetic and safety study of posaconazole tablets when given as antifungal prophylaxis. Patients were immunocompromised with underlying conditions including haematological malignancy, neutropenia post-chemotherapy, GVHD, and post HSCT. Posaconazole therapy was given for a median duration of 28&nbsp;days<em>.</em> Twenty patients received 200&nbsp;mg daily dose and 210&nbsp;patients received 300&nbsp;mg daily dose (following twice daily dosing on Day 1 in each cohort).</p><p>&nbsp;</p><p>The safety of posaconazole tablets and concentrate for solution for infusion were also investigated in a controlled study of treatment of invasive aspergillosis. The maximum duration of invasive aspergillosis treatment was similar to that studied with the oral suspension for salvage treatment and was longer than that with the tablets or concentrate for solution for infusion in prophylaxis.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;2.</strong> Adverse reactions by body system and frequency reported in clinical studies and/or post-marketing use*</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>thrombocytopenia, leukopenia, anaemia, eosinophilia, lymphadenopathy, splenic infarction</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura, pancytopenia, coagulopathy, haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>allergic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>hypersensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p><p>Rare:</p><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:bottom"><p>&nbsp;</p><p>adrenal insufficiency, blood gonadotropin decreased, pseudoaldosteronism</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>hyperglycaemia, hypoglycaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p><p>Uncommon:</p><p>Rare:</p></td><td colspan="2" style="vertical-align:bottom"><p>abnormal dreams, confusional state, sleep disorder</p><p>psychotic disorder, depression</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>paraesthesia, dizziness, somnolence, headache, dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>convulsions, neuropathy, hypoaesthesia, tremor, aphasia, insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>cerebrovascular accident, encephalopathy, peripheral neuropathy, syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>blurred vision, photophobia, visual acuity reduced</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td colspan="2" style="vertical-align:top"><p>diplopia, scotoma</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorder</strong></p><p>Rare:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>hearing impairment</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>long QT syndrome<sup>&sect;</sup>, electrocardiogram abnormal<sup>&sect;</sup>, palpitations, bradycardia, supraventricular extrasystoles, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>torsade de pointes, sudden death, ventricular tachycardia, cardio-respiratory arrest, cardiac failure, myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p><p>Common:</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>hypertension</p><p>hypotension, vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>pulmonary embolism, deep vein thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Uncommon:</p><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>&nbsp;</p><p>cough, epistaxis, hiccups, nasal congestion, pleuritic pain, tachypnoea</p><p>pulmonary hypertension, interstitial pneumonia, pneumonitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p>Very Common:</p><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>nausea</p><p>vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth, flatulence, constipation, anorectal discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>pancreatitis, abdominal distension, enteritis, epigastric discomfort, eructation, gastroesophageal reflux disease, oedema mouth</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>gastrointestinal haemorrhage, ileus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>liver function tests raised (ALT increased, AST increased, bilirubin increased, alkaline phosphatase increased, GGT increased)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>hepatocellular damage, hepatitis, jaundice, hepatomegaly, cholestasis, hepatic toxicity, hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic failure, hepatitis cholestatic, hepatosplenomegaly, liver tenderness, asterixis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Common:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>rash, pruritis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>mouth ulceration, alopecia, dermatitis, erythema, petechiae</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome, vesicular rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p>Uncommon:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>&nbsp;</p><p>back pain, neck pain, musculoskeletal pain, pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>acute renal failure, renal failure, blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>renal tubular acidosis, interstitial nephritis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p><p>Uncommon:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>menstrual disorder</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>breast pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site</strong> <strong>conditions</strong></p><p>Common:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>pyrexia (fever), asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>oedema, pain, chills, malaise, chest discomfort, drug intolerance, feeling jittery, mucosal inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>tongue oedema, face oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p>Uncommon:</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>altered medicine levels, blood phosphorus decreased, chest x‑ray abnormal</p></td></tr></tbody></table><p>* Based on adverse reactions observed with the oral suspension, gastro-resistant tablets, concentrate for solution for infusion, and gastro‑resistant powder and solvent for oral suspension.</p><p><sup>&sect;</sup> See section&nbsp;4.4.</p><p>&nbsp;</p><p><u>Description </u><u>of </u><u>selected </u><u>adverse </u><u>reactions</u></p><p><em>Hepatobiliary disorders</em></p><p>During post-marketing surveillance of posaconazole oral suspension, severe hepatic injury with fatal outcome has been reported (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><ul><li><u>Saudi Arabia: </u></li></ul><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose of posaconazole tablets.</p><p>&nbsp;</p><p>During clinical studies, patients who received posaconazole oral suspension doses up to 1,600&nbsp;mg/day experienced no different adverse reactions from those reported with patients at the lower doses. Accidental overdose was noted in one patient who took posaconazole oral suspension 1,200&nbsp;mg twice a day for 3&nbsp;days. No adverse reactions were noted by the investigator.</p><p>&nbsp;</p><p>Posaconazole is not removed by haemodialysis. There is no special treatment available in the case of overdose with posaconazole. Supportive care may be considered.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC&nbsp;code: J02AC04.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Posaconazole inhibits the enzyme lanosterol 14&alpha;-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis.</p><p>&nbsp;</p><p><u>Microbiology</u></p><p>Posaconazole has been shown <em>in vitro</em> to be active against the following microorganisms: <em>Aspergillus</em> species (<em>Aspergillus fumigatus</em>,<em> A. flavus</em>,<em> A. terreus</em>,<em> A. nidulans</em>,<em> A. niger</em>,<em> A. ustus</em>),<em> Candida</em> species (<em>Candida albicans, C. glabrata, C. krusei,</em> <em>C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis</em>), <em>Coccidioides immitis</em>, <em>Fonsecaea pedrosoi</em>,<em> </em>and<em> </em>species of <em>Fusarium, Rhizomucor</em>, <em>Mucor</em>, and <em>Rhizopus.</em> The microbiological data suggest that posaconazole is active against<em> Rhizomucor</em>, <em>Mucor</em>, and <em>Rhizopus; </em>however, the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents.</p><p>&nbsp;</p><p>The following <em>in vitro</em> data are available, but their clinical significance is unknown. In a surveillance study of &gt;&nbsp;3,000&nbsp;clinical mold isolates from 2010‑2018, 90&nbsp;% of non-<em>Aspergillus</em> fungi exhibited the following <em>in vitro</em> minimum inhibitory concentration (MIC): <em>Mucorales</em> spp (n=81) of 2&nbsp;mg/L; <em>Scedosporium apiospermum/S. boydii</em> (n=65) of 2&nbsp;mg/L; <em>Exophiala dermatiditis</em> (n=15) of 0.5&nbsp;mg/L, and <em>Purpureocillium lilacinum</em> (n=21) of 1&nbsp;mg/L.</p><p>&nbsp;</p><p><u>Resistance</u></p><p>Clinical isolates with decreased susceptibility to posaconazole have been identified. The principle mechanism of resistance is the acquisition of substitutions in the target protein, CYP51.</p><p>&nbsp;</p><p><u>Epidemiological Cut-off (ECOFF) Values for <em>Aspergillus spp.</em></u></p><p>The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology.</p><p>&nbsp;</p><p>EUCAST ECOFF values:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus flavus</em>: 0.5&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus fumigatus</em>: 0.5&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus nidulans</em>: 0.5&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus niger</em>: 0.5&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus terreus</em>: 0.25&nbsp;mg/L</p><p><u>&nbsp;</u></p><p>There are currently insufficient data to set clinical breakpoints for <em>Aspergillus </em>spp. ECOFF values do not equate to clinical breakpoints.</p><p><u>&nbsp;</u></p><p><u>Breakpoints</u></p><p>EUCAST MIC breakpoints for posaconazole [susceptible (S); resistant (R)]:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Candida albicans</em>: S&nbsp;&le;0.06&nbsp;mg/L, R&nbsp;&gt;0.06&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Candida tropicalis</em>: S&nbsp;&le;0.06&nbsp;mg/L, R&nbsp;&gt;0.06&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Candida parapsilosis</em>: S&nbsp;&le;0.06&nbsp;mg/L, R&nbsp;&gt;0.06&nbsp;mg/L</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Candida dubliniensis</em>: S &le;0.06&nbsp;mg/L, R &gt; 0.06&nbsp;mg/L</p><p><em>&nbsp;</em></p><p>There are currently insufficient data to set clinical breakpoints for other <em>Candida</em> species.</p><p>&nbsp;</p><p><u>Combination with other antifungal agents</u></p><p>The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies; however, there is currently no clinical evidence that combination therapy will provide an added benefit.</p><p>&nbsp;</p><p><u>Clinical experience</u></p><p><u>&nbsp;</u></p><p><em><u>Summary of posaconazole concentrate for solution for infusion and tablet study invasive aspergillosis</u></em></p><p>The safety and efficacy of posaconazole for the treatment of patients with invasive aspergillosis was evaluated in a double-blind controlled study (study-69) in 575&nbsp;patients with proven, probable, or possible invasive fungal infections per EORTC/MSG criteria.</p><p>&nbsp;</p><p>Patients were treated with posaconazole (n=288) concentrate for solution for infusion or tablet given at a dose of 300&nbsp;mg QD (BID on Day&nbsp;1). Comparator patients were treated with voriconazole (n=287) given IV at a dose of 6&nbsp;mg/kg BID Day&nbsp;1 followed by 4&nbsp;mg/kg BID, or orally at a dose of 300&nbsp;mg BID Day&nbsp;1 followed by 200&nbsp;mg BID. Median treatment duration was 67&nbsp;days (posaconazole) and 64&nbsp;days (voriconazole).</p><p>&nbsp;</p><p>In the intent-to-treat (ITT) population (all subjects who received at least one dose of study drug), 288 patients received posaconazole and 287 patients received voriconazole. The full analysis set population (FAS) is the subset of all subjects within the ITT population who were classified by independent adjudication as having proven or probable invasive aspergillosis: 163 subjects for posaconazole and 171 subjects for voriconazole. The all-cause mortality and global clinical response in these two populations are presented in Table 3 and 4, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;3. </strong>Posaconazole invasive aspergillosis treatment study&nbsp;1: all-cause mortality at Day&nbsp;42 and Day&nbsp;84, in the ITT and FAS populations</p><table border="0" cellspacing="0" cellpadding="0" style="width:660px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Posaconazole</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Voriconazole</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Population</p></td><td><p>N</p></td><td><p>n (%)</p></td><td><p>N</p></td><td><p>n (%)</p></td><td><p>Difference* (95&nbsp;% CI)</p></td></tr></thead><tbody><tr><td><p>Mortality in ITT at Day&nbsp;42</p></td><td><p>288</p></td><td><p>44 (15.3)</p></td><td><p>287</p></td><td><p>59 (20.6)</p></td><td><p>-5.3 % (-11.6, 1.0)</p></td></tr><tr><td><p>Mortality in ITT at Day 84</p></td><td><p>288</p></td><td><p>81 (28.1)</p></td><td><p>287</p></td><td><p>88 (30.7)</p></td><td><p>-2.5 % (-9.9, 4.9)</p></td></tr><tr><td><p>Mortality in FAS at Day 42</p></td><td><p>163</p></td><td><p>31 (19.0)</p></td><td><p>171</p></td><td><p>32 (18.7)</p></td><td><p>0.3% (-8.2, 8.8)</p></td></tr><tr><td><p>Mortality in FAS at Day 84</p></td><td><p>163</p></td><td><p>56 (34.4)</p></td><td><p>171</p></td><td><p>53 (31.0)</p></td><td><p>3.1% (-6.9, 13.1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>* Adjusted treatment difference based on Miettinen and Nurminen&rsquo;s method stratified by randomisation factor (risk for mortality/poor outcome), using Cochran-Mantel-Haenszel weighting scheme.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;4. </strong>Posaconazole invasive aspergillosis treatment study&nbsp;1: global clinical response at Week&nbsp;6 and Week 12 in the FAS population<strong> </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:660px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Posaconazole</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Voriconazole</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Population</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>Success (%)</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>Success (%)</p></td><td style="vertical-align:top"><p>Difference* (95&nbsp;% CI)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Global clinical response in the FAS at 6 weeks</p></td><td><p>163</p></td><td><p>73 (44.8)</p></td><td><p>171</p></td><td><p>78 (45.6)</p></td><td><p>-0.6 % (-11.2, 10.1)</p></td></tr><tr><td style="vertical-align:top"><p>Global clinical response in the FAS at 12 weeks</p></td><td><p>163</p></td><td><p>69 (42.3)</p></td><td><p>171</p></td><td><p>79 (46.2)</p></td><td><p>-3.4 % (-13.9, 7.1)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>* Successful Global Clinical Response was defined as survival with a partial or complete response</p><p>Adjusted treatment difference based on Miettinen and Nurminen&rsquo;s method stratified by randomisation factor (risk for mortality/poor outcome), using Cochran-Mantel-Haenszel weighting scheme.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em><u>Summary of posaconazole tablet bridging study</u></em></p><p>Study 5615 was a non-comparative multi-centre study performed to evaluate the pharmacokinetic properties, safety, and tolerability of posaconazole tablet. Study&nbsp;5615 was conducted in a similar patient population to that previously studied in the pivotal posaconazole oral suspension clinical program. The pharmacokinetics and safety data from Study 5615 were bridged to the existing data (including efficacy data) with the oral suspension.</p><p>&nbsp;</p><p>The subject population included: 1) patients with AML or MDS who had recently received chemotherapy and had developed or were anticipated to develop significant neutropenia, or 2) patients who had undergone a HSCT and were receiving immunosuppressive therapy for prevention or treatment of GVHD. Two different dosing groups were evaluated: 200&nbsp;mg twice daily on Day 1, followed by 200&nbsp;mg once daily thereafter (Part IA) and 300&nbsp;mg twice daily on Day 1, followed by 300&nbsp;mg once daily thereafter (Part 1B and Part 2).</p><p>&nbsp;</p><p>Serial PK samples were collected on Day 1 and at steady-state on Day 8 for all Part 1 subjects and a subset of Part 2 subjects. Moreover, sparse PK samples were collected at several days during steady state before the next dose (C<sub>min</sub>) for a larger subject population. Based on average C<sub>min</sub> concentrations, a predicted average concentration (C<sub>av</sub>) could be calculated for 186 subjects dosed with 300&nbsp;mg. PK analysis in patients of C<sub>av</sub> found that 81&nbsp;% of the subjects treated with the 300&nbsp;mg once daily dose attained steady state predicted C<sub>av</sub> between 500-2,500&nbsp;ng/mL. One subject (&lt;1&nbsp;%) had a predicted C<sub>av</sub> below 500&nbsp;ng/mL and 19&nbsp;% of the subjects had a predicted C<sub>av</sub> above 2,500&nbsp;ng/mL. Subjects achieved a mean predicted C<sub>av</sub> at steady state of 1,970&nbsp;ng/mL.</p><p>&nbsp;</p><p>In Table 5 a comparison is shown of exposure (C<sub>av</sub>) after administration of posaconazole tablet and posaconazole oral suspension at therapeutic doses in patients depicted as quartile analysis. Exposures after tablet administration are generally higher than, but overlapping with, exposures after administration of posaconazole oral suspension.</p><p><strong>&nbsp;</strong></p><p><strong>Table 5. </strong>C<sub>av</sub> quartile analyses of pivotal patient studies with posaconazole tablet and oral suspension</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Posaconazole tablet</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Posaconazole oral suspension</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Prophylaxis in AML and HSCT</strong></p><p><strong>Study 5615</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Prophylaxis in GVHD</strong></p><p><strong>Study 316</strong></p></td><td style="vertical-align:top"><p><strong>Prophylaxis in Neutropenia</strong></p><p><strong>Study 1899</strong></p></td><td style="vertical-align:top"><p><strong>Treatment &ndash; Invasive Aspergillosis</strong></p><p><strong>Study 0041</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>300&nbsp;mg once daily (Day&nbsp;1 300&nbsp;mg twice daily)*</strong></p></td><td style="vertical-align:top"><p><strong>200&nbsp;mg three times daily</strong></p></td><td style="vertical-align:top"><p><strong>200&nbsp;mg three times daily</strong></p></td><td style="vertical-align:top"><p><strong>200&nbsp;mg four times daily (hospitalized) then 400&nbsp;mg twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Quartile</strong></p></td><td style="vertical-align:top"><p><strong>pC<sub>av</sub> Range (ng/mL)</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>av</sub> Range (ng/mL)</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>av</sub> Range (ng/mL)</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>av</sub> Range (ng/mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Q1</strong></p></td><td style="vertical-align:top"><p>442 &ndash; 1,223</p></td><td style="vertical-align:top"><p>22 &ndash; 557</p></td><td style="vertical-align:top"><p>90 &ndash; 322</p></td><td style="vertical-align:top"><p>55 &ndash; 277</p></td></tr><tr><td style="vertical-align:top"><p><strong>Q2</strong></p></td><td style="vertical-align:top"><p>1,240 &ndash; 1,710</p></td><td style="vertical-align:top"><p>557 &ndash; 915</p></td><td style="vertical-align:top"><p>322 &ndash; 490</p></td><td style="vertical-align:top"><p>290 &ndash; 544</p></td></tr><tr><td style="vertical-align:top"><p><strong>Q3</strong></p></td><td style="vertical-align:top"><p>1,719 &ndash; 2,291</p></td><td style="vertical-align:top"><p>915 &ndash; 1,563</p></td><td style="vertical-align:top"><p>490 &ndash; 734</p></td><td style="vertical-align:top"><p>550 &ndash; 861</p></td></tr><tr><td style="vertical-align:top"><p><strong>Q4</strong></p></td><td style="vertical-align:top"><p>2,304 &ndash; 9,523</p></td><td style="vertical-align:top"><p>1,563 &ndash; 3,650</p></td><td style="vertical-align:top"><p>734 &ndash; 2,200</p></td><td style="vertical-align:top"><p>877 &ndash; 2,010</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>pC<sub>av</sub>: predicted C<sub>av</sub></p><p>C<sub>av</sub> = the average concentration when measured at steady state</p><p>*20 patients received 200&nbsp;mg once daily (Day 1 200&nbsp;mg twice daily)</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Summary of posaconazole oral suspension studies</u></em></p><p>&nbsp;</p><p><em>Invasive aspergillosis</em></p><p>Oral posaconazole suspension 800&nbsp;mg/day in divided doses was evaluated<strong><em> </em></strong>for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a non-comparative salvage therapy study (Study 0041). Clinical outcomes were compared with those in an external control group derived from a retrospective review of medical records. The external control group included 86&nbsp;patients treated with available therapy (as above) mostly at the same time and at the same sites as the patients treated with posaconazole. Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88&nbsp;%) and in the external control group (79&nbsp;%).</p><p>As shown in Table&nbsp;6, a successful response (complete or partial resolution)<strong><em> </em></strong>at the end of treatment was seen in 42&nbsp;% of posaconazole-treated patients compared to 26&nbsp;% of the external group. However, this was not a prospective, randomised controlled study and so all comparisons with the external control group should be viewed with caution.</p><p>&nbsp;</p><p><strong>Table&nbsp;6.</strong> Overall efficacy of posaconazole oral suspension at the end of treatment for invasive aspergillosis in comparison to an external control group</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Posaconazole</strong><strong> oral </strong><strong>suspension</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>External</strong><strong> control group</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall Response</p></td><td colspan="2" style="vertical-align:top"><p>45/107 (42&nbsp;%)</p></td><td colspan="2" style="vertical-align:top"><p>22/86 (26&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Success by Species</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All mycologically confirmed</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Aspergillus</em> spp.<sup><sup>[1]</sup></sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>34/76</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(45&nbsp;%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19/74</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(26&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A. fumigatus</em></p></td><td style="vertical-align:top"><p>12/29</p></td><td style="vertical-align:top"><p>(41&nbsp;%)</p></td><td style="vertical-align:top"><p>12/34</p></td><td style="vertical-align:top"><p>(35&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A. flavus</em></p></td><td style="vertical-align:top"><p>10/19</p></td><td style="vertical-align:top"><p>(53&nbsp;%)</p></td><td style="vertical-align:top"><p>3/16</p></td><td style="vertical-align:top"><p>(19&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A. terreus</em></p></td><td style="vertical-align:top"><p>4/14</p></td><td style="vertical-align:top"><p>(29&nbsp;%)</p></td><td style="vertical-align:top"><p>2/13</p></td><td style="vertical-align:top"><p>(15&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A. niger</em></p></td><td style="vertical-align:top"><p>3/5</p></td><td style="vertical-align:top"><p>(60&nbsp;%)</p></td><td style="vertical-align:top"><p>2/7</p></td><td style="vertical-align:top"><p>(29&nbsp;%)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Fusarium </em>spp<em>.</em></p><p>11&nbsp;of 24&nbsp;patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800&nbsp;mg/day in divided doses for a median of 124&nbsp;days and up to 212&nbsp;days. Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders.</p><p>&nbsp;</p><p><em>Chromoblastomycosis/Mycetoma</em></p><p>9&nbsp;of 11&nbsp;patients were successfully treated with posaconazole oral suspension 800&nbsp;mg/day in divided doses for a median of 268&nbsp;days and up to 377&nbsp;days. Five of these patients had chromoblastomycosis due to <em>Fonsecaea pedrosoi</em> and 4&nbsp;had mycetoma, mostly due to <em>Madurella </em>species.</p><p>&nbsp;</p><p><em>Coccidioidomycosis</em></p><p>11 of 16&nbsp;patients were successfully treated (at the end of treatment complete or partial resolution of signs and symptoms present at baseline<em>)</em> with posaconazole oral suspension 800&nbsp;mg/day in divided doses for a median of 296&nbsp;days and up to 460&nbsp;days.</p><p>&nbsp;</p><p><em>Prophylaxis of Invasive Fungal Infections (IFIs) (Studies</em><em>&nbsp;316 and</em><em>&nbsp;1899)</em></p><p>Two randomised, controlled prophylaxis studies were conducted among patients at high‑risk for developing invasive fungal infections.</p><p>&nbsp;</p><p>Study 316&nbsp;was a randomised, double-blind study of posaconazole oral suspension (200&nbsp;mg three times a day) versus fluconazole capsules (400&nbsp;mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD). The primary efficacy endpoint was the incidence of proven/probable IFIs at 16&nbsp;weeks post-randomisation as determined by an independent, blinded external expert panel. A key secondary endpoint was the incidence of proven/probable IFIs during the on-treatment period (first dose to last dose of study medicinal product + 7&nbsp;days). The majority (377/600, [63&nbsp;%]) of patients included had Acute Grade 2 or 3 or chronic extensive (195/600, [32.5&nbsp;%])<em> </em>GVHD at study start.<strong> </strong>The mean duration of therapy was 80&nbsp;days for posaconazole and 77&nbsp;days for fluconazole.</p><p><em>&nbsp;</em></p><p>Study 1899&nbsp;was a randomised, evaluator-blinded study of posaconazole oral suspension (200&nbsp;mg three times a day) versus fluconazole suspension (400&nbsp;mg once daily) or itraconazole oral solution (200&nbsp;mg twice a day) in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukaemia or myelodysplastic syndromes. The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period. A key secondary endpoint was the incidence of proven/probable IFIs at 100&nbsp;days post-randomisation. New diagnosis of acute myelogenous leukaemia was the most common underlying condition (435/602, [72&nbsp;%]). The mean duration of therapy was 29&nbsp;days for posaconazole and 25&nbsp;days for fluconazole/itraconazole.</p><p>&nbsp;</p><p>In both prophylaxis studies, aspergillosis was the most common breakthrough infection. See Table&nbsp;7 and 8 for results from both studies. There were fewer breakthrough <em>Aspergillus </em>infections in patients receiving posaconazole prophylaxis when compared to control patients.</p><p>&nbsp;</p><p><strong>Table </strong><strong>7.</strong> Results from clinical studies in prophylaxis of Invasive Fungal Infections</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Posaconazole oral suspension</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Control<sup>a</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>P-Value</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Proportion (%) of patients with proven/probable IFIs</strong></p></td></tr></thead><tbody><tr><td colspan="7"><p><strong>On-treatment period<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>1899<strong><sup>d</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>7/304 (2)</p></td><td colspan="2" style="vertical-align:top"><p>25/298 (8)</p></td><td colspan="2" style="vertical-align:top"><p>0.0009</p></td></tr><tr><td style="vertical-align:top"><p>316<strong><sup>e</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>7/291 (2)</p></td><td colspan="2" style="vertical-align:top"><p>22/288 (8)</p></td><td colspan="2" style="vertical-align:top"><p>0.0038</p></td></tr><tr><td colspan="7"><p><strong>Fixed-time period<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>1899<strong><sup>d</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>14/304 (5)</p></td><td colspan="2" style="vertical-align:top"><p>33/298 (11)</p></td><td colspan="2" style="vertical-align:top"><p>0.0031</p></td></tr><tr><td style="vertical-align:top"><p>316<strong><sup> d</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>16/301 (5)</p></td><td colspan="2" style="vertical-align:top"><p>27/299 (9)</p></td><td style="vertical-align:top"><p>0.0740</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>FLU = fluconazole&nbsp;; ITZ = itraconazole&nbsp;; POS = posaconazole.</p><p>A:&nbsp;&nbsp;&nbsp; FLU/ITZ (1899); FLU (316).</p><p>B:&nbsp;&nbsp;&nbsp; In 1899 this was the period from randomisation to last dose of study medicinal product plus 7&nbsp;days; in 316 it was the period from first dose to last dose of study medicinal product plus 7&nbsp;days.</p><p>C:&nbsp;&nbsp;&nbsp; In 1899, this was the period from randomisation to 100&nbsp;days post-randomisation; in 316 it was the period from the baseline day to 111&nbsp;days post-baseline.</p><p>D:&nbsp;&nbsp;&nbsp; All randomised</p><p>e:&nbsp;&nbsp;&nbsp;&nbsp; All treated</p><p>&nbsp;</p><p><strong>Table 8.</strong> Results from clinical studies in prophylaxis of Invasive Fungal Infections</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Study</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Posaconazole</strong> <strong>oral suspension</strong></p></td><td style="vertical-align:top"><p><strong>Control<sup>a</sup></strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Proportion (%) of patients with proven/probable Aspergillosis</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>On-treatment period<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>1899<strong><sup>d</sup></strong></p></td><td colspan="2"><p>2/304 (1)</p></td><td colspan="2"><p>20/298 (7)</p></td></tr><tr><td style="vertical-align:top"><p>316<strong><sup>e</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>3/291 (1)</p></td><td colspan="2" style="vertical-align:top"><p>17/288 (6)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Fixed-time period<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>1899<strong><sup>d</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>4/304 (1)</p></td><td colspan="2" style="vertical-align:top"><p>26/298 (9)</p></td></tr><tr><td style="vertical-align:top"><p>316<strong><sup> d</sup></strong></p></td><td colspan="2"><p>7/301 (2)</p></td><td colspan="2"><p>21/299 (7)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>FLU = fluconazole&nbsp;; ITZ = itraconazole&nbsp;; POS = posaconazole.</p><p>A:&nbsp;&nbsp;&nbsp; FLU/ITZ (1899); FLU (316).</p><p>B:&nbsp;&nbsp;&nbsp; In 1899 this was the period from randomisation to last dose of study medicinal product plus 7&nbsp;days; in 316 it was the period from first dose to last dose of study medicinal product plus 7&nbsp;days.</p><p>C:&nbsp;&nbsp;&nbsp; In 1899, this was the period from randomisation to 100&nbsp;days post-randomisation; in 316 it was the period from the baseline day to 111&nbsp;days post-baseline.</p><p>D:&nbsp;&nbsp;&nbsp; All randomised</p><p>e:&nbsp;&nbsp;&nbsp;&nbsp; All treated</p><p>&nbsp;</p><p>In Study&nbsp;1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS&nbsp;49/304&nbsp;(16&nbsp;%) vs. FLU/ITZ&nbsp;67/298&nbsp;(22&nbsp;%) p=&nbsp;0.048]. Based on Kaplan-Meier estimates, the probability of survival up to day<strong>&nbsp;</strong>100 after randomisation, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P=&nbsp;0.0354) as well as IFI-related deaths (P =&nbsp;0.0209).</p><p>&nbsp;</p><p>In Study&nbsp;316, overall mortality was similar (POS, 25&nbsp;%; FLU, 28&nbsp;%); however, the proportion of IFI-related deaths was significantly lower in the POS group&nbsp;(4/301) compared with the FLU group&nbsp;(12/299; P=&nbsp;0.0413).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>There is limited paediatric experience for posaconazole tablets.</p><p>Three patients 14-17&nbsp;years of age were treated with posaconazole concentrate for solution for infusion and tablet 300&nbsp;mg/day (BID on Day&nbsp;1 followed by QD thereafter) in the study of treatment of invasive aspergillosis.</p><p>The safety and efficacy of posaconazole (Noxafil gastro-resistant powder and solvent for oral suspension; Noxafil concentrate for solution for infusion) have been established in paediatric patients&nbsp;2 to less than 18&nbsp;years of age. Use of posaconazole in these age groups is supported by evidence from adequate and well-controlled studies of posaconazole in adults and pharmacokinetic and safety data from paediatric studies (see section&nbsp;5.2). No new safety signals associated with the use of posaconazole in paediatric patients were identified in the paediatric studies (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Safety and efficacy in paediatric patients below the age of 2&nbsp;years have not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><u>Electrocardiogram evaluation</u></p><p>Multiple, time-matched ECGs collected over a 12&nbsp;hour period were obtained before and during administration of posaconazole oral suspension (400&nbsp;mg twice daily with high fat meals) from 173&nbsp;healthy male and female volunteers aged 18&nbsp;to 85&nbsp;years. No clinically relevant changes in the mean QTc (Fridericia) interval from baseline were observed.</p><p>&nbsp;</p><p>[1] Includes other less common species or species unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic / Pharmacodynamic relationships</u></p><p>A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed. The critical ratio for subjects with <em>Aspergillus</em> infections was ~200. It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with <em>Aspergillus</em> (see sections&nbsp;4.2 and 5.2 on recommended dose regimens).</p><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>Posaconazole tablets are absorbed with a median T<sub>max</sub> of 4 to 5&nbsp;hours and exhibits dose proportional pharmacokinetics after single and multiple dosing up to 300&nbsp;mg.</p><p>&nbsp;</p><p>Following a single dose administration of 300&nbsp;mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC<sub>0-72 hours </sub>and C<sub>max</sub> were higher compared to administration under fasted condition (51&nbsp;% and 16&nbsp;% for AUC<sub>0-72 hours </sub>and C<sub>max</sub> respectively). Based on a population pharmacokinetic model, posaconazole C<sub>av</sub> is increased 20&nbsp;% when given with a meal compared to a fasted state.</p><p>&nbsp;</p><p>Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients. The reason for this time-dependency is not completely understood.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Posaconazole, after administration of the tablet, has a mean apparent volume of distribution of 394 L (42&nbsp;%), ranging between 294-583&nbsp;L among the studies in healthy volunteers.</p><p><strong><u>&nbsp;</u></strong></p><p>Posaconazole is highly protein bound (&gt;&nbsp;98&nbsp;%), predominantly to serum albumin.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Posaconazole does not have any major circulating metabolites and its concentrations are unlikely to be altered by inhibitors of CYP450&nbsp;enzymes. Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed. The excreted metabolites in urine and faeces account for approximately 17&nbsp;% of the administered radiolabelled dose.</p><p><strong>&nbsp;</strong></p><p><u>Elimination</u></p><p>Posaconazole after administration of the tablets, is slowly eliminated with a mean half-life (t<sub>&frac12;</sub>) of 29&nbsp;hours (range 26&nbsp;to 31&nbsp;hours) and a mean apparent clearance ranging from 7.5 to 11&nbsp;L/hr. After administration of <sup>14</sup>C-posaconazole, radioactivity was predominantly recovered in the faeces (77&nbsp;% of the radiolabelled dose) with the major component being parent compound (66&nbsp;% of the radiolabelled dose). Renal clearance is a minor elimination pathway, with 14&nbsp;% of the radiolabelled dose excreted in urine (&lt;&nbsp;0.2&nbsp;% of the radiolabelled dose is parent compound). Steady-state plasma concentrations are attained by Day 6 at the 300&nbsp;mg dose (once daily after twice daily loading dose at Day 1).</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p>Based on a population pharmacokinetic model evaluating posaconazole pharmacokinetics, steady state posaconazole concentrations were predicted in patients administered posaconazole concentrate for solution for infusion or tablets 300&nbsp;mg once a day following BID dosing on Day&nbsp;1 for the treatment of invasive aspergillosis and prophylaxis of invasive fungal infections.</p><p>&nbsp;</p><p><strong>Table&nbsp;9. </strong>Population predicted median (10<sup>th </sup>percentile, 90<sup>th</sup> percentile) posaconazole steady state plasma concentrations in patients following administration of posaconazole concentrate for solution for infusion or tablets 300&nbsp;mg QD (BID on Day&nbsp;1)</p><table border="1" cellspacing="0" cellpadding="0" style="width:506px"><tbody><tr><td style="vertical-align:top"><p><strong>Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Population</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong><sub>av</sub></strong><strong> (ng/mL)</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong><sub>min</sub></strong><strong> (ng/mL)</strong></p></td></tr><tr><td rowspan="2"><p>Tablet-(Fasted)</p></td><td style="vertical-align:top"><p>Prophylaxis</p></td><td style="vertical-align:bottom"><p>1,550</p><p>(874; 2,690)</p></td><td style="vertical-align:bottom"><p>1,330</p><p>(667; 2,400)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of Invasive Aspergillosis</p></td><td style="vertical-align:bottom"><p>1,780</p><p>(879; 3,540)</p></td><td style="vertical-align:bottom"><p>1,490</p><p>(663; 3,230)</p></td></tr><tr><td rowspan="2"><p>Concentrate for Solution for Infusion</p></td><td style="vertical-align:top"><p>Prophylaxis</p></td><td style="vertical-align:bottom"><p>1,890</p><p>(1,100; 3,150)</p></td><td style="vertical-align:bottom"><p>1,500</p><p>(745; 2,660)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of Invasive Aspergillosis</p></td><td style="vertical-align:bottom"><p>2,240</p><p>(1,230; 4,160)</p></td><td style="vertical-align:bottom"><p>1,780</p><p>(874; 3,620)</p></td></tr></tbody></table><p>&nbsp;</p><p>The population pharmacokinetic analysis of posaconazole in patients suggests that race, sex, renal impairment and disease (prophylaxis or treatment) have no clinically meaningful effect on the pharmacokinetics of posaconazole.</p><p><em>&nbsp;</em></p><p><em>Children (&lt;&nbsp;18&nbsp;years)</em></p><p>There is limited (n=3) paediatric experience with posaconazole tablets.</p><p>The pharmacokinetics of posaconazole oral suspension have been evaluated in paediatric patients. Following administration of 800&nbsp;mg per day of posaconazole oral suspension as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12&nbsp;patients 8&nbsp;&ndash; 17&nbsp;years of age (776&nbsp;ng/mL) were similar to concentrations from 194&nbsp;patients 18 &ndash; 64&nbsp;years of age (817&nbsp;ng/mL). No pharmacokinetic data are available from paediatric patients less than 8&nbsp;years of age. Similarly, in the prophylaxis studies, the mean steady-state posaconazole average concentration (C<sub>av</sub>) was comparable among ten adolescents (13‑17&nbsp;years of age) to C<sub>av</sub> achieved in adults (&ge;&nbsp;18&nbsp;years of age).</p><p>&nbsp;</p><p><em>Gender</em></p><p>The pharmacokinetics of posaconazole tablets are comparable in men and women.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No overall differences in safety were observed between the geriatric patients and younger patients.</p><p>&nbsp;</p><p>The population pharmacokinetic model of posaconazole concentrate for solution for infusion and tablets indicates that posaconazole clearance is related to age. Posaconazole C<sub>av</sub> is generally comparable between young and elderly patients (&ge;&nbsp;65&nbsp;years of age); however, the C<sub>av</sub> is increased by 11&nbsp;% in the very elderly (&ge;&nbsp;80&nbsp;years). It is, therefore, suggested to closely monitor very elderly patients (&ge;&nbsp;80&nbsp;years) for adverse events.</p><p>&nbsp;</p><p>The pharmacokinetics of posaconazole tablets are comparable in young and elderly subjects (&ge;&nbsp;65&nbsp;years of age).</p><p>&nbsp;</p><p>Pharmacokinetic differences based upon age are not considered to be clinically relevant; therefore, no dose adjustment is required.</p><p>&nbsp;</p><p><em>Race</em></p><p>There is insufficient data among different races with posaconazole tablets.</p><p>&nbsp;</p><p>There was a slight decrease (16&nbsp;%) in the AUC and C<sub>max</sub> of posaconazole oral suspension in Black subjects relative to Caucasian subjects. However, the safety profile of posaconazole between the Black and Caucasian subjects was similar.</p><p>&nbsp;</p><p><em>Weight</em></p><p>The population pharmacokinetic model of posaconazole concentrate for solution for infusion and tablets indicates that posaconazole clearance is related to weight. In patients &gt;&nbsp;120&nbsp;kg, the C<sub>av</sub> is decreased by 25&nbsp;% and in patients &lt;50&nbsp;kg, the C<sub>av</sub> is increased by 19&nbsp;%.</p><p>It is, therefore, suggested to closely monitor for breakthrough fungal infections in patients weighing more than 120&nbsp;kg.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18,&nbsp;Cl<sub> cr</sub> &ge;&nbsp;20&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) on posaconazole pharmacokinetics; therefore, no dose adjustment is required. In subjects with severe renal impairment (n=6, Cl<sub> cr</sub> &lt;&nbsp;20&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), the AUC of posaconazole was highly variable [&gt;&nbsp;96&nbsp;% CV (coefficient of variance)] compared to other renal groups [&lt;&nbsp;40&nbsp;% CV]. However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended. Posaconazole is not removed by haemodialysis.</p><p>&nbsp;</p><p>Similar recommendations apply to posaconazole tablets; however, a specific study has not been conducted with the posaconazole tablets.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>After a single oral dose of 400&nbsp;mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6‑fold higher compared to that for matched control subjects with normal hepatic function. Unbound concentrations were not determined and it cannot be excluded that there is a larger increase in unbound posaconazole exposure than the observed 60&nbsp;% increase in total AUC. The elimination half-life (t<sub>&frac12;</sub>) was prolonged from approximately 27&nbsp;hours up to ~43&nbsp;hours in respective groups. No dose adjustment is recommended for patients with mild to severe hepatic impairment but caution is advised due to the potential for higher plasma exposure.</p><p>&nbsp;</p><p>Similar recommendations apply to posaconazole tablets; however, a specific study has not been conducted with the posaconazole tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As observed with other azole antifungal agents, effects related to inhibition of steroid hormone synthesis were seen in repeated-dose toxicity studies with posaconazole. Adrenal suppressive effects were observed in toxicity studies in rats and dogs at exposures equal to or greater than those obtained at therapeutic doses in humans.</p><p>&nbsp;</p><p>Neuronal phospholipidosis occurred in dogs dosed for &sup3;&nbsp;3&nbsp;months at lower systemic exposures than those obtained at therapeutic doses in humans. This finding was not seen in monkeys dosed for one year. In twelve-month neurotoxicity studies in dogs and monkeys, no functional effects were observed on the central or peripheral nervous systems at systemic exposures greater than those achieved therapeutically.</p><p>&nbsp;</p><p>Pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats. These findings are not necessarily indicative of a potential for functional changes in humans.</p><p>&nbsp;</p><p>No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at maximal plasma concentrations 8.5-fold&nbsp;greater than the concentrations obtained at therapeutic doses in humans. Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 2.1‑fold greater than that achieved therapeutically. Increased systolic and arterial blood pressures (up to 29&nbsp;mm‑Hg) were seen in rats and monkeys at systemic exposures 2.1‑fold and 8.5‑fold&nbsp;greater, respectively, than those achieved with the human therapeutic doses.</p><p>&nbsp;</p><p>Reproduction, peri- and postnatal development studies were conducted in rats. At exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability. In rabbits, posaconazole was embryotoxic at exposures greater than those obtained at therapeutic doses. As observed with other azole antifungal agents, these effects on reproduction were considered to be due to a treatment-related effect on steroidogenesis.</p><p>&nbsp;</p><p>Posaconazole was not genotoxic in <em>in vitro</em> and <em>in vivo</em> studies. Carcinogenicity studies did not reveal special hazards for humans.</p><p>&nbsp;</p><p>In a nonclinical study using intravenous administration of posaconazole in very young dogs (dosed from 2-8 weeks of age) an increase in the incidence of brain ventricle enlargement was observed in treated animals as compared with concurrent control animals. No difference in the incidence of brain ventricle enlargement between control and treated animals was observed following the subsequent 5&nbsp;month treatment-free period. There were no neurologic, behavioural or developmental abnormalities in the dogs with this finding, and a similar brain finding was not seen with either oral posaconazole administration to juvenile dogs (4&nbsp;days to&nbsp;9 months of age) or intravenous posaconazole administration to juvenile dogs (10&nbsp;weeks to 23&nbsp;weeks of age). The clinical significance of this finding is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Hypromellose acetate succinate</p><p>Cellulose, microcrystalline</p><p>Hydroxypropylcellulose (E463)</p><p>Silica dental type</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coat</u></p><p>polyvinyl alcohol</p><p>macrogol 3350</p><p>titanium dioxide (E171)</p><p>talc</p><p>iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

2	years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Noxafil 100&nbsp;mg gastro-resistant tablets are packaged in a PVC/ polychlorotrifluoroethylene laminate blister with push-through aluminium lidding.</p><p>&nbsp;</p><p>Noxafil gastro-resistant tablets are packaged in a blister in cartons of 24 (2x12) or 96 (8x12) tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme (UK) Limited
120 Moorgate
London
EC2M 6UR
United Kingdom



Manufacturer:
N.V. Organon  
Kloosterstraat 6, 5349 AB Oss
The Netherlands


Packaging Site
Schering- Plough Labo N.V., Industriepark 30, 2220 Heist-op-den-Berg, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>